id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-268155-b8lqo52f	Farrugia, Albert	Plasma from donors convalescent from SARS-CoV-2 infection – A matter of priorities	2020-06-12		.txt	text/plain	443	37	45	title: Plasma from donors convalescent from SARS-CoV-2 infection – A matter of priorities In the interim, donor panels for hyperimmune Ig production may be constructed and an optimal path for the provision of this medicine may be developed, hopefully with harmonisation between the major regulatory agencies. Convalescent plasma harvested from voluntary donors in state blood services is at risk of being deflected from therapeutic use through preferential patient allocation to clinical trials for other Covid-19 therapies funded by large pharmaceutical companies. Given the continued body of evidence and public effort in the collection and use of convalescent plasma, it is to be hoped that this treatment will be considered as a first line modality and will not be obstructed by commercial considerations. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma Effectiveness of convalescent plasma therapy in severe COVID-19 patients Donor centers for convalescent plasma	./cache/cord-268155-b8lqo52f.txt	./txt/cord-268155-b8lqo52f.txt